T. Rowe Price Associates’s Chemours CC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.71M | Buy |
168,424
+26,146
| +18% | +$455K | ﹤0.01% | 1552 |
|
|
2025
Q4 | $1.68M | Sell |
142,278
-1,747
| -1% | -$22.4K | ﹤0.01% | 1835 |
|
|
2025
Q3 | $2.28M | Buy |
144,025
+6,395
| +5% | +$92.8K | ﹤0.01% | 1674 |
|
|
2025
Q2 | $1.58M | Buy |
137,630
+22,841
| +20% | +$257K | ﹤0.01% | 1758 |
|
|
2025
Q1 | $1.55M | Buy |
114,789
+7,188
| +7% | +$119K | ﹤0.01% | 1734 |
|
|
2024
Q4 | $1.82M | Buy |
107,601
+7,572
| +8% | +$147K | ﹤0.01% | 1698 |
|
|
2024
Q3 | $2.03M | Buy |
100,029
+3,934
| +4% | +$80.4K | ﹤0.01% | 1629 |
|
|
2024
Q2 | $2.17M | Buy |
96,095
+4,750
| +5% | +$124K | ﹤0.01% | 1520 |
|
|
2024
Q1 | $2.4M | Buy |
91,345
+2,932
| +3% | +$83.5K | ﹤0.01% | 1488 |
|
|
2023
Q4 | $2.79M | Buy |
88,413
+4,792
| +6% | +$130K | ﹤0.01% | 1398 |
|
|
2023
Q3 | $2.35M | Buy |
83,621
+1,439
| +2% | +$49.4K | ﹤0.01% | 1399 |
|
|
2023
Q2 | $3.03M | Buy |
82,182
+784
| +1% | +$23.9K | ﹤0.01% | 1338 |
|
|
2023
Q1 | $2.44M | Buy |
81,398
+804
| +1% | +$26.5K | ﹤0.01% | 1403 |
|
|
2022
Q4 | $2.47M | Sell |
80,594
-15,532
| -16% | -$466K | ﹤0.01% | 1391 |
|
|
2022
Q3 | $2.37M | Buy |
96,126
+673
| +0.7% | +$22.2K | ﹤0.01% | 1393 |
|
|
2022
Q2 | $3.06M | Sell |
95,453
-1,816
| -2% | -$66.8K | ﹤0.01% | 1502 |
|
|
2022
Q1 | $3.06M | Buy |
97,269
+7,564
| +8% | +$237K | ﹤0.01% | 1566 |
|
|
2021
Q4 | $3.01M | Buy |
89,705
+874
| +1% | +$27.2K | ﹤0.01% | 1582 |
|
|
2021
Q3 | $2.58M | Sell |
88,831
-2,362
| -3% | -$76.5K | ﹤0.01% | 1636 |
|
|
2021
Q2 | $3.17M | Sell |
91,193
-15,026
| -14% | -$498K | ﹤0.01% | 1602 |
|
|
2021
Q1 | $2.96M | Buy |
106,219
+20,073
| +23% | +$534K | ﹤0.01% | 1584 |
|
|
2020
Q4 | $2.14M | Sell |
86,146
-6,668
| -7% | -$159K | ﹤0.01% | 1618 |
|
|
2020
Q3 | $1.94M | Sell |
92,814
-21,882
| -19% | -$422K | ﹤0.01% | 1557 |
|
|
2020
Q2 | $1.76M | Sell |
114,696
-325
| -0.3% | -$4.11K | ﹤0.01% | 1568 |
|
|
2020
Q1 | $1.02M | Buy |
115,021
+8,526
| +8% | +$123K | ﹤0.01% | 1689 |
|
|
2019
Q4 | $1.93M | Sell |
106,495
-1,930
| -2% | -$32.1K | ﹤0.01% | 1615 |
|
|
2019
Q3 | $1.62M | Buy |
108,425
+539
| +0.5% | +$8.77K | ﹤0.01% | 1632 |
|
|
2019
Q2 | $2.59M | Buy |
107,886
+87
| +0.1% | +$2.56K | ﹤0.01% | 1513 |
|
|
2019
Q1 | $4.01M | Buy |
107,799
+6,640
| +7% | +$242K | ﹤0.01% | 1428 |
|
|
2018
Q4 | $2.85M | Sell |
101,159
-12,763
| -11% | -$404K | ﹤0.01% | 1477 |
|
|
2018
Q3 | $4.49M | Buy |
113,922
+10,841
| +11% | +$474K | ﹤0.01% | 1469 |
|
|
2018
Q2 | $4.57M | Buy |
103,081
+9,179
| +10% | +$457K | ﹤0.01% | 1443 |
|
|
2018
Q1 | $4.57M | Buy |
93,902
+14,125
| +18% | +$706K | ﹤0.01% | 1441 |
|
|
2017
Q4 | $3.99M | Sell |
79,777
-3,030
| -4% | -$159K | ﹤0.01% | 1456 |
|
|
2017
Q3 | $4.19M | Sell |
82,807
-7,080
| -8% | -$334K | ﹤0.01% | 1461 |
|
|
2017
Q2 | $3.41M | Sell |
89,887
-81
| -0.1% | -$3.19K | ﹤0.01% | 1465 |
|
|
2017
Q1 | $3.46M | Buy |
89,968
+10,706
| +14% | +$322K | ﹤0.01% | 1472 |
|
|
2016
Q4 | $1.75M | Buy |
79,262
+433
| +0.5% | +$8.89K | ﹤0.01% | 1599 |
|
|
2016
Q3 | $1.26M | Sell |
78,829
-37,600
| -32% | -$429K | ﹤0.01% | 1662 |
|
|
2016
Q2 | $959K | Buy |
116,429
+18,532
| +19% | +$165K | ﹤0.01% | 1719 |
|
|
2016
Q1 | $685K | Buy |
97,897
+17,462
| +22% | +$87.7K | ﹤0.01% | 1848 |
|
|
2015
Q4 | $431K | Sell |
80,435
-11,720
| -13% | -$74.9K | ﹤0.01% | 2020 |
|
|
2015
Q3 | $596K | Buy |
+92,155
| New | +$965K | ﹤0.01% | 1876 |
|
Other funds holding CC
VPM
VCM
WHCM
T. Rowe Price Associates's CC Position: Q1 2026 in Review
T. Rowe Price Associates increased its Chemours (CC) stake by 18% in Q1 2026, buying an estimated $455K and bringing the position to 168,424 shares worth $3.71M. The position accounts for ﹤0.01% of the portfolio, ranked #1552.
T. Rowe Price Associates first reported a position in CC in Q3 2015 and has held it in 43 quarters since. The position peaked at $4.57M in Q1 2018. 448 funds tracked by Wall St. Rank hold CC as of Q1 2026.
- T. Rowe Price Associates held 168,424 shares of Chemours worth $3.71M as of Q1 2026.
- T. Rowe Price Associates bought 26,146 Chemours shares in Q1 2026, an estimated $455K.
- Chemours made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1552 holding.
- T. Rowe Price Associates first reported a position in Chemours in Q3 2015 and has held it in 43 quarters since.
- T. Rowe Price Associates's Chemours position peaked at $4.57M in Q1 2018.
- 448 funds tracked by Wall St. Rank held Chemours as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.